Crown Bioscience has restructured its leadership team and hinted at acquisitions in the U.S. and Europe.
The preclinical services firm—which is owned by JSR Life Sciences—shared details of the changes to its executive team this week, confirming the appointment of Michael Prosser as chief business officer. Alex Slater will take on responsibility for development of its business in the Asia-Pacific market as part of his expanded vice president of business development role.
The latest appointments come just a few months after Crown teamed up with fellow JSR Life Sciences unit Medical & Biological Laboratories to further expand its preclinical services in Japan.
CEO Armin Spura, Ph.D., said the new top table changes reflected both the growth of Crown’s business over the past few years and a desire to position for further expansion.
“Crown Bioscience has grown significantly in recent years, consistently exceeding its annual growth target, and in FY21 we were delighted to record bookings growth of over 40%,” Spura said in a statement.
“With these changes announced today and under Michael's continued leadership, we are confident we are putting in place a commercial team that optimally positions Crown Bioscience for our next phase of growth,” the CEO added.
Crown said it added more than 400 new customers in the 2021 financial year, and this extra demand had led the company to “accelerated investments” in the company’s global footprint such as renovating its lab facilities in the APAC region.
“In Europe and the United States, parallel investments are also planned for site expansions and strategic acquisitions,” Crown added.